Skip to main content
Clinical Trials/NCT00419055
NCT00419055
Terminated
Not Applicable

Outpatient Percutaneous Coronary Intervention in a Selected, Stable Patient Population

University of Pennsylvania0 sites100 target enrollmentAugust 2004

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
University of Pennsylvania
Enrollment
100
Primary Endpoint
The primary endpoints are patient satisfaction and safety.
Status
Terminated
Last Updated
14 years ago

Overview

Brief Summary

To determine the safety and feasibility of same day discharge after elective coronary percutaneous intervention in a selected stable patient population. The hypothesis to be tested is that in an appropriately selected stable coronary artery disease population post percutaneous coronary intervention, early discharge is safe and feasible.

Detailed Description

A select stable population of patients undergoing percutaneous coronary intervention are randomized to standard of care in-hospital stay for one night or early discharge to a nearby hotel. During PCI, patients receive bivalirudin as their anti-coagulant and also must be eligible for an angioseal closure device. Patients that stay overnight in the hotel must be accompanied by a family member. They return to the cath lab the next day for groin check and blood work. Satisfaction questionnaires are filled out by all patients.

Registry
clinicaltrials.gov
Start Date
August 2004
End Date
August 2006
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with stable coronary artery disease scheduled for elective percutaneous coronary intervention

Exclusion Criteria

  • Patients with acute coronary syndrome, patients with an MI within 30 days, an ejection fraction \<30%, those with history of IV Dye allergy, creatinine level\>2.2, those with increased risk of infection, those with history of bleeding diathesis or anemia (hemoglobin\<11.0 g/dl, platelets \<100,000 tho/ul)

Outcomes

Primary Outcomes

The primary endpoints are patient satisfaction and safety.

Time Frame: 30 days

Similar Trials